To investigate the progression of Pten-deficient malignancies, prostate cancer progression was chosen as the initial model because a good understanding of the role of Pten in this disease has been gained from other prostate-specific Pten knockout mouse model studies [20], [21], [23], [25]. Here, PTEN is linked to prostate carcinoma.